A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection

J Hepatol. 2015 May;62(5):1204-6. doi: 10.1016/j.jhep.2014.12.025. Epub 2015 Jan 2.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / adverse effects
  • Benzazepines* / administration & dosage
  • Benzazepines* / adverse effects
  • Carbamates
  • Drug Monitoring
  • Drug Resistance, Viral
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / adverse effects
  • Female
  • Hepacivirus* / drug effects
  • Hepacivirus* / genetics
  • Hepatitis C, Chronic* / drug therapy
  • Hepatitis C, Chronic* / virology
  • Humans
  • Imidazoles* / administration & dosage
  • Imidazoles* / adverse effects
  • Indoles* / administration & dosage
  • Indoles* / adverse effects
  • Isoquinolines* / administration & dosage
  • Isoquinolines* / adverse effects
  • Male
  • Middle Aged
  • Pyrrolidines
  • Sulfonamides* / administration & dosage
  • Sulfonamides* / adverse effects
  • Treatment Outcome
  • Valine / analogs & derivatives

Substances

  • 8-cyclohexyl-N-((dimethylamino)sulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)cycloprop(d)indolo(2,1-a)(2)benzazepine-5-carboxamide
  • Antiviral Agents
  • Benzazepines
  • Carbamates
  • Enzyme Inhibitors
  • Imidazoles
  • Indoles
  • Isoquinolines
  • Pyrrolidines
  • Sulfonamides
  • Valine
  • daclatasvir
  • asunaprevir